Skip to Content

Positive results presented by the VISION trial

Addition of 177Lu-PSMA-617 to the standard treatment significantly improved radiographic progression-free survival versus standard treatment by 5.3 months with a significant reduction and the risk of progression or death.

Man at the doctor

Get access

If you are a doctor, nurse, or other health professionals, you can access the entire article by creating a profile on BestPractice Nordic.

Back to top